Table 2.
Baseline characteristics of patients after PCI.
| Variables | Group1 | Group2 | P value |
|---|---|---|---|
| (n = 20) | (n = 33) | ||
| Clinical characteristics | |||
| BMI (kg/m2), mean ± SD | 24.76 ± 2.07 | 26.53 ± 2.50 | 0.010 |
| DAC (cm), mean ± SD | 92.20 ± 8.57 | 91.64 ± 9.97 | 0.834 |
| Heart rate (bpm), mean ± SD | 74.10 ± 10.86 | 68.58 ± 13.28 | 0.123 |
| Systolic BP (mmHg), mean ± SD | 140.90 ± 23.19 | 136.97 ± 23.39 | 0.555 |
| Diastolic BP (mmHg), mean ± SD | 80.40 ± 14.84 | 79.12 ± 19.10 | 0.799 |
| Laboratory parameters | |||
| TnI (ng/mL), median (IQR 25%−75%) | 0.59 (0.06–3.77) | 0.02 (0.003–0.54) | 0.061 |
| TnT (ng/mL), median (IQR 25%−75%) | 0.07 (0.03–0.78) | 0.18 (0.01–0.12) | 0.133 |
| CK (U/L), median (IQR 25%−75%) | 61.50 (56.00–122.50) | 95.00 (59.00–250.50) | 0.368 |
| CK–MB (ng/mL), median (IQR 25%−75%) | 1.80 (1.45–4.63) | 1.2 (0.83–4.60) | 0.349 |
| LDH (U/L), median (IQR 25%−75%) | 175.00 (154.00–186.75) | 194.00 (150.00–222.00) | 0.826 |
| NT–proBNP (pg/mL), median (IQR 25%−75%) | 855.00 (137.00–1438.25) | 229.50 (106.00–848.75) | 0.106 |
| Scr (μmol/L), mean ± SD | 72.67 ± 10.65 | 67.11 ± 10.07 | 0.062 |
| FBG (mmol/L), median (IQR 25%−75%) | 6.50 (5.90–9.58) | 6.35 (6.03–9.18) | 0.732 |
| HBA1c (%), median (IQR 25%−75%) | 7.96 (6.03–8.65) | 6.60 (6.10–7.65) | 0.293 |
| TC (mmol/L), mean ± SD | 3.84 ± 0.97 | 3.75 ± 1.01 | 0.747 |
| TG (mmol/L), mean ± SD | 1.51 ± 0.60 | 1.32 ± 0.60 | 0.274 |
| HDL (mmol/L), mean ± SD | 1.15 ± 0.59 | 1.11 ± 0.27 | 0.723 |
| LDL (mmol/L), mean ± SD | 2.01 ± 0.81 | 2.06 ± 0.77 | 0.831 |
| Sodium (mmol/L), mean ± SD | 140.77 ± 2.36 | 139.61 ± 2.00 | 0.075 |
| Potassium (mmol/L), mean ± SD | 4.01 ± 0.43 | 3.98 ± 0.32 | 0.729 |
| TyG index, mean ± SD | 7.43 ± 0.62 | 7.29 ± 0.58 | 0.447 |
| Echocardiography, mean ±SD | |||
| LVEF (%) | 60.90 ± 9.78 | 63.22 ± 7.16 | 0.324 |
| E/A | 0.77 ± 0.22 | 0.83 ± 0.23 | 0.388 |
| Cardiac index (L/min/m2) | 2.65 ± 0.51 | 2.86 ± 0.60 | 0.206 |
| Concomitant medication, n (%) | |||
| Statin | 16 (80) | 31 (94) | 0.184 |
| Aspirin | 16 (80) | 27 (82) | 0.870 |
| Clopidogrel/Ticagrelor | 18 (90) | 21 (64) | 0.035 |
| ACE inhibitor/ARB | 2 (10) | 25 (76) | < 0.001 |
| Beta blocker | 12 (60) | 21 (64) | 0.791 |
| Calcium channel blocker | 6 (30) | 13 (39) | 0.489 |
| Insulin | 2 (10) | 4 (12) | 0.813 |
BMI, body mass index; BP, blood pressure; TnI, troponin I; IQR, interquartile range; TnT, troponin T; CK, creatine kinase; CK-MB, creatine kinase isoenzyme-MB; LDH, lactate dehydrogenase; NT-proBNP, N-terminal pro-B-type natriuretic peptide; Scr, serum creatinine; FBG, fasting blood glucose; HBA1c, hemoglobin A1c; TC, total cholesterol; TG, triacylglycerol; HDL, high-density protein; LDL, low-density protein; TyG, triglyceride glucose index, calculated as the ln [fasting triglycerides (mg/dL) × fasting plasma glucose (mg/dL)/2]; LVEF, left-ventricular ejection fraction; E/A, ratio of early to late transmitral flow velocity; ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker. P < 0.05 is significant (bold values).